Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Adagene Inc (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ADAG
Nasdaq
8731
https://www.adagene.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Adagene Inc (ADR)
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
- Mar 7th, 2024 9:01 pm
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
- Feb 27th, 2024 1:00 pm
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
- Feb 9th, 2024 11:00 am
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
- Jan 17th, 2024 12:00 pm
Adagene Inc.'s (NASDAQ:ADAG) market cap surged US$34m last week, retail investors who have a lot riding on the company were rewarded
- Jan 10th, 2024 10:56 am
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
- Jan 4th, 2024 10:00 am
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
- Nov 3rd, 2023 4:00 pm
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
- Oct 30th, 2023 1:40 pm
Are Medical Stocks Lagging Medpace (MEDP) This Year?
- Oct 13th, 2023 1:40 pm
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
- Oct 12th, 2023 12:00 pm
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
- Sep 27th, 2023 1:40 pm
Potential Upside For Adagene Inc. (NASDAQ:ADAG) Not Without Risk
- Sep 9th, 2023 1:06 pm
Adagene to Present at Investor and Scientific Conferences in September
- Sep 8th, 2023 2:45 am
Are Medical Stocks Lagging Adagene (ADAG) This Year?
- Sep 7th, 2023 1:40 pm
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
- Aug 31st, 2023 11:32 am
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
- May 25th, 2023 1:40 pm
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
- May 4th, 2023 1:00 pm
Adagene Announces Updates to its Board of Directors
- Apr 28th, 2023 11:00 am
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
- Apr 18th, 2023 1:17 pm
Adagene Full Year 2022 Earnings: US$1.85 loss per share (vs US$1.83 loss in FY 2021)
- Mar 31st, 2023 10:34 am
Scroll